-
1
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: An update
-
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-1374
-
(2009)
Hepatology
, vol.49
, Issue.4
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
2
-
-
0024981607
-
Recombinant interferon alfa therapy for chronic hepatitis C A randomized, double-blind, placebo-controlled trial
-
Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321(22):1506-1510
-
(1989)
N Engl J Med
, vol.321
, Issue.22
, pp. 1506-1510
-
-
Di Bisceglie, A.M.1
Martin, P.2
Kassianides, C.3
Lisker-Melman, M.4
Murray, L.5
Waggoner, J.6
Goodman, Z.7
Banks, S.M.8
Hoofnagle, J.H.9
-
3
-
-
0031902847
-
Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection
-
Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, Simpson KJ, Hayes PC. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998;42(4):570-575 (Pubitemid 28186578)
-
(1998)
Gut
, vol.42
, Issue.4
, pp. 570-575
-
-
Haydon, G.H.1
Jarvis, L.M.2
Blair, C.S.3
Simmonds, P.4
Harrison, D.J.5
Simpson, K.J.6
Hayes, P.C.7
-
4
-
-
0030907270
-
Clinical relevance of hepatitis C virus genotypes
-
Simmonds P. Clinical relevance of hepatitis C virus genotypes. Gut 1997;40(3):291-293 (Pubitemid 27145637)
-
(1997)
Gut
, vol.40
, Issue.3
, pp. 291-293
-
-
Simmonds, P.1
-
5
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-355
-
(2004)
Ann Intern Med
, vol.140
, Issue.5
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr., H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
Ramadori, G.7
Bodenheimer Jr., H.8
Bernstein, D.9
Rizzetto, M.10
Zeuzem, S.11
Pockros, P.J.12
Lin, A.13
Ackrill, A.M.14
-
6
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
DOI 10.1016/S0140-6736(01)06102-5
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-965 (Pubitemid 32913521)
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.-H.9
Albrecht, J.K.10
-
7
-
-
10644264391
-
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
-
DOI 10.1002/hep.20467
-
Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40(6):1260-1265 (Pubitemid 39656999)
-
(2004)
Hepatology
, vol.40
, Issue.6
, pp. 1260-1265
-
-
Dalgard, O.1
Bjoro, K.2
Hellum, K.B.3
Myrvang, B.4
Ritland, S.5
Skaug, K.6
Raknerud, N.7
Bell, H.8
-
8
-
-
20544443172
-
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
-
DOI 10.1056/NEJMoa042608
-
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352(25):2609-2617 (Pubitemid 41007847)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.25
, pp. 2609-2617
-
-
Mangia, A.1
Santoro, R.2
Minerva, N.3
Ricci, G.L.4
Carretta, V.5
Persico, M.6
Vinelli, F.7
Scotto, G.8
Bacca, D.9
Annese, M.10
Romano, M.11
Zechini, F.12
Sogari, F.13
Spirito, F.14
Andriulli, A.15
-
9
-
-
9144257569
-
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
-
DOI 10.1056/NEJM199601113340203
-
Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334(2):77-81 (Pubitemid 26017933)
-
(1996)
New England Journal of Medicine
, vol.334
, Issue.2
, pp. 77-81
-
-
Enomoto, N.1
Sakuma, I.2
Asahina, Y.3
Kurosaki, M.4
Murakami, T.5
Yamamoto, C.6
Ogura, Y.7
Izumi, N.8
Marumo, F.9
Sato, C.10
-
10
-
-
47149083069
-
Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy
-
DOI 10.1002/hep.22339
-
El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008;48(1):38-47 (Pubitemid 351975529)
-
(2008)
Hepatology
, vol.48
, Issue.1
, pp. 38-47
-
-
El-Shamy, A.1
Nagano-Fujii, M.2
Sasase, N.3
Imoto, S.4
Kim, S.-R.5
Hotta, H.6
-
11
-
-
33644656689
-
Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy
-
DOI 10.1111/j.1440-1746.2005.04024.x
-
Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 2005;20(9):1401-1409 (Pubitemid 43960839)
-
(2005)
Journal of Gastroenterology and Hepatology
, vol.20
, Issue.9
, pp. 1401-1409
-
-
Hamano, K.1
Sakamoto, N.2
Enomoto, N.3
Izumi, N.4
Asahina, Y.5
Kurosaki, M.6
Ueda, E.7
Tanabe, Y.8
Maekawa, S.9
Itakura, J.10
Watanabe, H.11
Kakinuma, S.12
Watanabe, M.13
-
12
-
-
0033754631
-
Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy
-
Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K, Takahashi N, Kinoshita M, Kumada H. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology 2000;32(5):1138-1144
-
(2000)
Hepatology
, vol.32
, Issue.5
, pp. 1138-1144
-
-
Chayama, K.1
Suzuki, F.2
Tsubota, A.3
Kobayashi, M.4
Arase, Y.5
Saitoh, S.6
Suzuki, Y.7
Murashima, N.8
Ikeda, K.9
Takahashi, N.10
Kinoshita, M.11
Kumada, H.12
-
13
-
-
22344457187
-
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
-
DOI 10.1159/000086064
-
Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005;48(6):372-380 (Pubitemid 41003622)
-
(2005)
Intervirology
, vol.48
, Issue.6
, pp. 372-380
-
-
Akuta, N.1
Suzuki, F.2
Sezaki, H.3
Suzuki, Y.4
Hosaka, T.5
Someya, T.6
Kobayashi, M.7
Saitoh, S.8
Watahiki, S.9
Sato, J.10
Matsuda, M.11
Kobayashi, M.12
Arase, Y.13
Ikeda, K.14
Kumada, H.15
-
14
-
-
77952959964
-
Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load
-
Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T, Katano Y, Goto H. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol 2010;25(6):1072-1078
-
(2010)
J Gastroenterol Hepatol
, vol.25
, Issue.6
, pp. 1072-1078
-
-
Toyoda, H.1
Kumada, T.2
Tada, T.3
Arakawa, T.4
Hayashi, K.5
Honda, T.6
Katano, Y.7
Goto, H.8
-
15
-
-
77949353338
-
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients
-
Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 2010;5(2):e9032
-
(2010)
PLoS One
, vol.5
, Issue.2
-
-
Donlin, M.J.1
Cannon, N.A.2
Aurora, R.3
Li, J.4
Wahed, A.S.5
Di Bisceglie, A.M.6
Tavis, J.E.7
-
16
-
-
34547130793
-
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy
-
DOI 10.1128/JVI.00487-07
-
Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007;81(15):8211-8224 (Pubitemid 47101507)
-
(2007)
Journal of Virology
, vol.81
, Issue.15
, pp. 8211-8224
-
-
Donlin, M.J.1
Cannon, N.A.2
Yao, E.3
Li, J.4
Wahed, A.5
Taylor, M.W.6
Belle, S.H.7
Di Bisceglie, A.M.8
Aurora, R.9
Tavis, J.E.10
-
17
-
-
0032861258
-
Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection
-
DOI 10.1002/hep.510300405
-
Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999;30(4):1045-1053 (Pubitemid 29458295)
-
(1999)
Hepatology
, vol.30
, Issue.4
, pp. 1045-1053
-
-
Murakami, T.1
Enomoto, N.2
Kurosaki, M.3
Izumi, N.4
Marumo, F.5
Sato, C.6
-
18
-
-
60049083515
-
Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy
-
Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med Virol 2009;81(3):459-466
-
(2009)
J Med Virol
, vol.81
, Issue.3
, pp. 459-466
-
-
Hayashi, K.1
Katano, Y.2
Honda, T.3
Ishigami, M.4
Itoh, A.5
Hirooka, Y.6
Nakano, I.7
Urano, F.8
Yoshioka, K.9
Toyoda, H.10
Kumada, T.11
Goto, H.12
-
19
-
-
0036117777
-
Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon
-
DOI 10.1016/S0002-9270(02)03975-8, PII S0002927002039758
-
Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, Ukai K, Yano M, Takagi K, Hattori M, Kakumu S, Yoshioka K. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Am J Gastroenterol 2002;97(4):988-998 (Pubitemid 34408259)
-
(2002)
American Journal of Gastroenterology
, vol.97
, Issue.4
, pp. 988-998
-
-
Kobayashi, M.1
Watanabe, K.2
Ishigami, M.3
Murase, K.4
Ito, H.5
Ukai, K.6
Yano, M.7
Takagi, K.8
Hattori, M.9
Kakumu, S.10
Yoshioka, K.11
-
20
-
-
69549137892
-
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
-
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 2009;52(6):301-309
-
(2009)
Intervirology
, vol.52
, Issue.6
, pp. 301-309
-
-
Akuta, N.1
Suzuki, F.2
Hirakawa, M.3
Kawamura, Y.4
Yatsuji, H.5
Sezaki, H.6
Suzuki, Y.7
Hosaka, T.8
Kobayashi, M.9
Saitoh, S.10
Arase, Y.11
Ikeda, K.12
Kumada, H.13
-
21
-
-
0038649813
-
Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b
-
DOI 10.1111/j.1572-0241.2003.07469.x
-
Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol 2003;98(6):1377-1383 (Pubitemid 36741537)
-
(2003)
American Journal of Gastroenterology
, vol.98
, Issue.6
, pp. 1377-1383
-
-
Saito, T.1
Ito, T.2
Ishiko, H.3
Yonaha, M.4
Morikawa, K.5
Miyokawa, A.6
Mitamura, K.7
-
22
-
-
0141615503
-
Amino acid substitutions in PKR-elF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy
-
DOI 10.1016/S1386-6346(03)00164-5
-
Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Sato C, Izumi N, Watanabe M. Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res 2003;26(4):268-274 (Pubitemid 37184514)
-
(2003)
Hepatology Research
, vol.26
, Issue.4
, pp. 268-274
-
-
Watanabe, H.1
Nagayama, K.2
Enomoto, N.3
Itakura, J.4
Tanabe, Y.5
Sato, C.6
Izumi, N.7
Watanabe, M.8
-
23
-
-
17144463221
-
Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
-
Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18(9):5208-5218 (Pubitemid 28388104)
-
(1998)
Molecular and Cellular Biology
, vol.18
, Issue.9
, pp. 5208-5218
-
-
Gale Jr., M.1
Blakely, C.M.2
Kwieciszewski, B.3
Tan, S.-L.4
Dossett, M.5
Tang, N.M.6
Korth, M.J.7
Polyak, S.J.8
Gretch, D.R.9
Katze, M.G.10
-
24
-
-
68749109781
-
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
-
Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009;16(8):586-594
-
(2009)
J Viral Hepat
, vol.16
, Issue.8
, pp. 586-594
-
-
Hiramatsu, N.1
Oze, T.2
Yakushijin, T.3
Inoue, Y.4
Igura, T.5
Mochizuki, K.6
Imanaka, K.7
Kaneko, A.8
Oshita, M.9
Hagiwara, H.10
Mita, E.11
Nagase, T.12
Ito, T.13
Inui, Y.14
Hijioka, T.15
Katayama, K.16
Tamura, S.17
Yoshihara, H.18
Imai, Y.19
Kato, M.20
Yoshida, Y.21
Tatsumi, T.22
Ohkawa, K.23
Kiso, S.24
Kanto, T.25
Kasahara, A.26
Takehara, T.27
Hayashi, N.28
more..
-
25
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461(7262):399-401
-
(2009)
Nature
, vol.461
, Issue.7262
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
Simon, J.S.4
Shianna, K.V.5
Urban, T.J.6
Heinzen, E.L.7
Qiu, P.8
Bertelsen, A.H.9
Muir, A.J.10
Sulkowski, M.11
McHutchison, J.G.12
Goldstein, D.B.13
-
26
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105-1109
-
(2009)
Nat Genet
, vol.41
, Issue.10
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
Kurosaki, M.4
Matsuura, K.5
Sakamoto, N.6
Nakagawa, M.7
Korenaga, M.8
Hino, K.9
Hige, S.10
Ito, Y.11
Mita, E.12
Tanaka, E.13
Mochida, S.14
Murawaki, Y.15
Honda, M.16
Sakai, A.17
Hiasa, Y.18
Nishiguchi, S.19
Koike, A.20
Sakaida, I.21
Imamura, M.22
Ito, K.23
Yano, K.24
Masaki, N.25
Sugauchi, F.26
Izumi, N.27
Tokunaga, K.28
Mizokami, M.29
more..
-
27
-
-
77949831342
-
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure-a genome-wide association study
-
Jan 7
-
Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure-a genome-wide association study. Gastroenterology 2010 Jan 7
-
(2010)
Gastroenterology
-
-
Rauch, A.1
Kutalik, Z.2
Descombes, P.3
Cai, T.4
Di Iulio, J.5
Mueller, T.6
Bochud, M.7
Battegay, M.8
Bernasconi, E.9
Borovicka, J.10
Colombo, S.11
Cerny, A.12
Dufour, J.F.13
Furrer, H.14
Gunthard, H.F.15
Heim, M.16
Hirschel, B.17
Malinverni, R.18
Moradpour, D.19
Mullhaupt, B.20
Witteck, A.21
Beckmann, J.S.22
Berg, T.23
Bergmann, S.24
Negro, F.25
Telenti, A.26
Bochud, P.Y.27
more..
|